Vitreo Retinal Associates

Publications

Christine Nichols Kay, M.D.

PUBLICATIONS (peer-reviewed)

[In print or forthcoming]

Yang P, Pardon LP, Ho, AC, Lauer, AK, Yoon D, Boye SE, Boye SL, Roman AJ, Wu V, Garafalo AV, Sumaroka A, Swider M, Viarbitskaya I, Aleman TS, Pennesi ME, Kay CN, Fujita KP, Cideciyan AV. Safety and Efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2 multicentre, open-label, unilateral dose escalation study. Lancet Vol 404, Issue 10456,, P962-970, September 7, 2024.

Birch DG, Cheetham JK, Daiger SP, Hoyng C, Kay C, McDonald IM, Pennesi ME, Sullivan LS. Overcoming the challenges to clinical development of X-linked retinitis pigmentosa therapies: proceedings of an expert panel. Transl Vis Sci Technol. 2023 Jun; 12(6):5.

Samuel G. Jacobson, Artur V. Cideciyan, Allen C. Ho, Alejandro J. Roman, Vivian Wu, Alexandra V. Garafalo, Alexander Sumaroka, Arun K. Krishnan, Malgorzata Swider, Abraham A. Mascio, Christine N. Kay, Dan Yoon, Kenji P. Fujita, Sanford L. Boye, Igor V. Peshenko, Alexander M. Dizhoor, Shannon E. Boye. Night vision restored in days after decades of congenital blindness. iScience, 2022

Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther. 2021 Feb 3;29(2):464-488.

Gregori NZ, Hussain RM, Kay CN, Lam BL, Dermer H, Davis JL. Current Concepts and Emerging Gene Therapies for Inherited Retinal Diseases. Int Ophthalmol Clin. 2019 Winter;59(1):83-110.

Duncan JL, Liang W, Maguire MG, Audo I, Ayala AR, Birch DG, Carroll J, Cheetham JK, Esposti SD, Durham TA, Erker L, Farsiu S, Ferris FL 3rd, Heon E, Hufnagel RB, Iannaccone A, Jaffe GJ, Kay CN, Michaelides M, Pennesi ME, Sahel JA; Foundation Fighting Blindness Consortium Investigator Group. Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity. Am J Ophthalmol. 2020 Nov;219:87-100.

Strampe MR, Huckenpahler AL, Higgins BP, Tarima S, Visotcky A, Stepien KE, Kay CN, Carroll J. Intraobserver Repeatability and Interobserver Reproducibility of Ellipsoid Zone Measurements in Retinitis Pigmentosa. Transl Vis Sci Technol. 2018 Jun 4;7(3):13

Dedania VS, Ghodasra DH, Kay CN, Roseman R, Johnson MW. CILIOCHOROIDAL EFFUSION AND ACUTE MACULAR NEURORETINOPATHY ASSOCIATED WITH CERVICAL TRACTION THERAPY. Retin Cases Brief Rep. 2018 Winter;12(1):24-28.

Langlo, C.S., Erker, L.R., Parker, M., Patterson, E.J., Higgins, B.P., Summerfelt, P., Razeen, M.M., Collison, F.T., Fishman, G.A., Kay, C.N., Zhang, J., Weleber, R.G., Yang, P., Pennesi, M.E., Lam, B.L., Chulay, J.D., Dubra, A., Hauswirth, W.W., Wilson, D.J., Carroll, J., ACHM-001 Study Group. Repeatability and longitudinal assessment of foveal cone structure in CNGB3-associated achromatopsia. Retina. 2017 Jan 31. doi: 10.1097/IAE.0000000000001434.

Sun LW, Johnson RD, Langlo CS, Cooper RF, Razeen MM, Russillo MC, Dubra A, Connor TB Jr, Han DP, Pennesi ME, Kay CN, Weinberg DV, Stepien KE, Carroll J. Assessing Photoreceptor Structure in Retinitis Pigmentosa and Usher Syndrome. Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2428-42.

Langlo C.S., Patterson E.J., Higgins B.P., Summerfelt P., Razeen M.M., Erker L.R., Parker M., Collison F.T., Fishman G.A., Kay C.N., Zhang J., Weleber R.G., Yang P., Wilson D.J., Pennesi M.E., Lam B.L., Chiang J., Chulay J.D., Dubra A., Hauswirth W.W., Carroll J., ACHM-001 Study Group. Residual foveal cone structure in CNGB3-associated achromatopsia. Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):3984-95. doi: 10.1167/iovs.16-19313.

Sun LW, Johnson RD, Langlo CS, Cooper RF, Razeen MM, Russillo MC, Dubra A, Connor TB Jr, Han DP, Pennesi ME, Kay CN, Weinberg DV, Stepien KE, Carroll J. Assessing Photoreceptor Structure in Retinitis Pigmentosa and Usher Syndrome. Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2428-42. doi: 10.1167/iovs.15-18246.

Dedania VS, Ghodasra DH, Kay CN, Roseman R, Johnson MW. “Ciliochoroidal Effusion and Acute Macular Neuroretinopathy Associated with Cervical Traction Therapy.” Accepted to Retina Cases and Brief Reports.

Choi C, Zhang L, Abramoff MD, Sonka M, Shifera A, Kay CN. Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration with OCT segmentation volumetric analysis. Ophthalmic Surgery Lasers and Imaging. 2016 Mar 1;47(3):245-51

Shifera AS, Kay CN. Early-onset X-linked retinitis pigmentosa in a heterozygous female harboring an intronic donor splice site mutation in the retinitis pigmentosa GTPase regulator gene. Ophthalmic Genetics. 2015;36(3):251-6. doi: 10.3109/13816810.2013.879597

Chen JJ, Sohn EH, Mahajan VM, Kay CN, Boldt HC, Folk JC, Russell SR. “Response of Foveal Cystoid Changes from Idiopathic Juxtafoveal Telangiectasia to Carbonic Anhydrase Inhibitors.” Retina. 2014 Jul;34(7):1400-6.

Bhullar SS, Gray MJ, Kay CN. “Role for rapid surgical intervention in uveal effusion syndrome with associated optic neuropathy.” Ophthalmic Surg Lasers Imaging Retina. 2014 Apr 4;45(3):e11-3. doi: 10.3928/23258160-20140331-04.

Cohen J, Bhullar S, Kasuga D, Boye S, Elhalis H, Kay CN. “Retinal pigment epithelial detachment in ABCA4-associated Stargardt disease.” Ophthalmic Surgery Lasers and Imaging. 2013 Jul 1;44(4):401-4.

Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Dyka FM, Kasuga D, Ayala AE, Van Vliet K, Agbandje-McKenna M, Hauswirth WW, Boye SL, Boye SE. “Targeting Photoreceptors Via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors.” PLoS One 2013 Apr 26;8(4):e62097.

Bhalla S, Joshi D, Bhullar S, Kasuga D, Park Y, Kay CN. Long term follow-up data for efficacy and safety of treatment of retinitis pigmentosa with valproic acid.” British Journal Ophthalmology 2013 Jul;97(7):895-9.

Hollsten JE, McClintock M, Samy H, Peden M, Kay CN. “Fulminant chorioretinitis and papillitis secondary to coxsackievirus B virus presenting as acute posterior multifocal placoid pigment epitheliopathy with positive response to IVIG.” Accepted to Retina Cases and Brief Reports.

McClintock M, Peden MC, Kay CN. “Spectral domain optical coherence tomography findings in siblings with CNGB3-associated achromatopsia.” Adv. Exp. Med. Biol 2014;801:551-7.

Boye SL, Peshenko IV, Huang WC, Min SH, McDoom I, Kay CN, Liu X, Dyka FM, Foster TC, Umino Y, Karan S, Jacobson SG ,Baehr W, Dizhoor A, Hauswirth WW and Boye SE. “AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis.” Hum Mol Gene Therapy 2013 Feb;24(2):189-202.

Russell SR, Sohn EH, Boldt HC, Folk JC, Tarantola RM, Kay CN, Mahajan VM. “Elimination of infusion bubbles and uncontrolled reflux in the Alcon constellation vitrectomy vision system.” Retina 2013 Apr;33(4):803-6.

Kay CN, Quiram P, Mahajan VM. “23-Gauge Pediatric Vitrectomy using Limbus-based Trocar-Cannulas.” Retina. 2012 May;32(5):1023-7.

Kay CN, Abramoff MD,  Mullins RF, Kinnick TR, Lee K, Chung MM, Sohn EH, Stone EM. “Three dimensional distribution of the vitelliform lesion, photoreceptors, and retinal pigment epithelium in the macula of patients with Best vitelliform macular dystrophy.” Arch Ophthalmol. 2012 Mar;130(3):357-64.

Kay CN, Pavan PR, Small LB, Zhang T, Zamba GKD, Cohen SM. “Familial Trends in a Population with Macular Holes.”  Retina. 2012 Apr;32(4):754-9.

Kay CN, Tarantola RM, Gehrs KM, Folk JC, Mahajan VB, Boldt HC, Syed N, Russell SR. “Uveitis Following Intravitreal Bevacizumab Injection: A Non-Infectious Cluster.” Ophthalmic Surgery Lasers and Imaging. 2011 Jul-Aug;42(4):292-6.

Kay CN, Elkins KA, Folk JC. “Resolution of refractory macular edema due to branch retinal vein occlusion after Ozurdex implantation.” Retina Cases and Brief Reports. 2012 Winter;6(1):72-5. doi: 10.1097/ICB.0b013e3182051feb

Kinnick TR, Mullins RF, Dev S, Leys M, Mackey D, Kay CN, Lam BL, Fishman GA, Traboulsi E, Stone EM.  “Autosomal Recessive Vitelliform Macular Dystrophy in a Large Cohort of Vitelliform Macular Disease Patients.” Retina. 2011 Mar;31(3):581-95.

Tarantola RM, Elkins KA, Kay CN, Folk JC.  “Photoreceptor Recovery Following Laser Photocoagulation and Albendazole in Diffuse Unilateral Subacute Neuroretinitis.”  Arch Ophthalmol. 2011 May;129(5):669-71.

Kay CN, Saunders T, Pavan PR. “Ocular Injuries Sustained in Paintball Trauma.” Graefe’s Archive for Clinical and Experimental Ophthalmology 2010 Mar;248(3):331-2.

Potcoava M, Kay CN, Kim MK, Richards DW. “In vitro imaging of ophthalmic tissue by digital interference holography.” Journal of Modern Optics 2009.

Kay CN, Pavan PR, Burrows A, Martino AZ. “Neurosensory Retinal Detachment of the Macula in Retinal Phototoxicity Documented by Optical Coherence Tomography.” Retinal Cases and Brief Reports.  2010 Spring;4(2):143-5. doi: 10.1097/ICB.0b013e3181997ce7.

Kay CN, Gendy MG, Lujan BJ, Punjabi OS, Gregori G, Flynn HW. “Composite Spectral Domain Optical Coherence Tomography Images of Diabetic Tractional Retinal Detachment.” Ophthalmic Surgery Lasers and Imaging 2008; 39:S99-S103.

(Kay) Nichols C, Pincus DW, Bhatti MT. “Optociliary Shunt Vessels.”  Neurology 64: 1443. April 2005.

[Submitted & In Preparation]

Margaret R. Strampe, Alison L. Huckenpahler, Mr. Brian P. Higgins , Kimberly E. Stepien , Dr. Christine N. Kay, Joseph Carroll. Repeatability of ellipsoid zone measurements in retinitis pigmentosa. Submitted to TVST.

Min SH, Boye SL, Ryals RC, Ruan Q, Sun J, Dyka F, Hauswirth WW, Boye SE, Kay CN. Long-term restoration of visual function in the CNGB3/NRL double knockout mouse, a cone-dominant model of CNGB3-achromatopsia. In preparation.

PUBLICATIONS (invited authorship/non peer-reviewed)

Kay CN. Subretinal Gene Therapy Delivery. (Book Chapter, Operative Techniques in Vitreoretinal Surgery.) 2020.

Kay CN, Boye S and Boye SE. Clinical In Vivo Gene Therapy (Ocular Disorders.) Molecular Therapy. 2020

Kay CN. Retinal Gene Therapies in Clinical Trials: A proliferation of clinical trials means hope for patients. Retinal Physician, March 2019.

Kay CN. “Logistics of Genetic Testing: An Overview for Retina Specialists.” Retinal Physician. November 2017.

Kay CN. “Gene Therapy: The new frontier for inherited retinal disease.” Retina Specialist. March 2017.

Hu JK, Griffeth W, Kay CN. “Interview with Dr. Robert MacLaren on clinical implications of his landmark study on retinal gene therapy in patients with choroideremia.” ASRS publication 2014, invited editorial.

Kay CN, Joshi S, Gallagher P. “Ocular infection and inflammation: UVEITIS.” Focus-ED CME publication.  Editors: Slonim CB, Raizman MA, Eichenbaum DA. Vol 1, Issue 2, Winter 2009.

Kay CN, Sohn E, Abramoff MD. “Biomarkers in Retinal Disease.” Retinal Physician.

 

M. Brandon Parrott, M.D., Ph.D.

Publications

Kuriyan, AE, Albini TT, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, Parrott MB, Rosenfeld Pj, Flynn HW, Goldberg JL: Vision loss after intravitreal injection of autologous “stem cells” for AMD. New England Journal of Medicine 2017: 376:11:1047-1053.

Wykoff CC, Parrott MB, Flynn HW Jr, Shi W, Miller D, Alfonso EC: Nosocomial acute-onset
postoperative endophthalmitis at a university teaching hospital (2002-2009). American Journal of Ophthalmology 2010: Sep 150(3):392-398.

Cavalcante LL, Cavalcante ML, Murray TG, Vigoda MM, Piña Y, Decatur CL, Davis RP, Olmos LC, Schefler AC, Parrott MB, Alliman KJ, Flynn HW, Moshfeghi AA: Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clinical Ophthalmology 2010: May 25(4):519-524.

Parrott MB: Evolution of the treatment of neovascular AMD in the age of anti-VEGF agents. The Ophthalmology Report 2010: 3(3):16-20.

Parrott, MB: The evolution of current and future treatments for neovascular AMD. The
Ophthalmology Report 2009: 2(2):16-20.

Campos SK, Parrott MB, Barry MA: Metabolically biotinylated pIX-modified adenovirus for single-step affinity purification of viral vectors. Molecular Therapy 2004: 9(6):942-54.

Blum JS, Parrott MB, Mikos AG and Barry MA: Early osteoblastic differentiation induced by dexamethasone enhances adenoviral gene delivery to marrow stromal cells. Journal of Orthopaedic Research 2003: 22(2):411-416.

Parrott MB, Adams KE, Mercier GT, Mok H, Campos SK, and Barry MA: Metabolically biotinylated adenovirus for cell-targeting, ligand screening, and vector purification. Molecular Therapy 2003: 8(4):688-700.

Takahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, and Barry MA: Selection of chronic lymphocytic leukemia targeting peptides. Cancer Research 2003: 63(17):5213-5217.

Barry MA, Campos SK, Ghosh D, Adams KE, Mok H, Mercier GT, and Parrott MB: Biotinylated gene therapy vectors. Expert Opinion in Biological Therapy 2003: 3(6):925-940.

Barry MA, Takahashi S, and Parrott MB: Selection of Peptides on Phage. In Vector Targeting for Therapeutic Gene Delivery. (DT Curiel and JT Douglas Eds.) John Wiley & Sons, Inc. New York, NY 2002.

Parrott MB and Barry MA: Metabolic biotinylation of secreted and cell surface proteins from mammalian cells. BBRC 2001: 281:993-1000.

Parrott MB and Barry MA: Metabolic biotinylation of recombinant proteins in mammalian cells and in mice. Molecular Therapy 2000: 1(1):96-104.

Dr. Siva Iyer, M.D.

Publications

Idiopathic Orbital Inflammation in the Postpartum Period Associated With Preeclampsia.

Journal of neuro-ophthalmology: the official journal of the North American Neuro-Ophthalmology Society
2022

The Vitreous Ecosystem in Diabetic Retinopathy: Insight into the Patho-Mechanisms of Disease.
International journal of molecular sciences
2021

Peripheral Retinal Neovascularization in a Patient with Sarcoidosis and Cocaine-Associated Autoimmunity.
Case reports in ophthalmological medicine
2021

Exacerbation of pigment epithelial detachment following aflibercept: A case of bevacizumab rescue.
American journal of ophthalmology case reports
2021

Effect of pattern scanning laser on macular thickness in diabetic retinopathy.
Therapeutic advances in ophthalmology
2021

Bilateral anterior segment dysgenesis and persistent fetal vasculature associated with terminal 10q26 deletion.
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2021

Utility of wound cultures in the management of open globe injuries: a 5-year retrospective review.
Journal of ophthalmic inflammation and infection
2020

Treatment of Recurrent Primary Cutaneous Mucinous Carcinoma of the Eyelid with Modified Wide Local Excision.
Case reports in ophthalmological medicine
2020

Endogenous Endophthalmitis: yield of the diagnostic evaluation.
BMC ophthalmology
2020

Eicosanoid Profiles in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy.
International journal of molecular sciences
2020

Bilateral pseudohypopyon causing white eyes in a patient with lymphoma.
Lancet (London, England)
2020

Surgical management of diabetic tractional retinal detachments.
Survey of ophthalmology
2019

Exercise band-induced lens dislocations: A case series.
American journal of ophthalmology case reports
2019

Dosimetric dependence of ocular structures on eye size and shape for external radiation fields of electrons, photons, and neutrons.
Journal of radiological protection : official journal of the Society for Radiological Protection
2019

Vision loss secondary to orbital extension of rhabdomyosarcoma in an adult.
Clinical & experimental ophthalmology
2018

Ophthalmic artery occlusion after chiropractic neck manipulation.
Acta ophthalmologica
2018

Multiloculated Ciliary Body Cysts and Lenticular Coloboma: A Rare Phenotypic Variation Associated With Persistent Fetal Vasculature.
Journal of pediatric ophthalmology and strabismus
2018

A scalable and deformable stylized model of the adult human eye for radiation dose assessment.
Physics in medicine and biology
2018

A Young Patient With Floaters.
JAMA ophthalmology
2018

Intralenticular Ozurdex® – One Year Later.
Case reports in ophthalmology
2017

Honors

Christine Nichols Kay, M.D.

2018 – ASRS Senior Honor Award
2017 – Inducted into Macula Society
2017 – Inducted into Retina Society
2012 – Honor Award, American Society of Retina Specialists
2008–2009 – Chief Resident, USF Ophthalmology Residency
2009 – USF Health Science Research Day: Outstanding Poster in Clinical Studies and Case Reports
2008 – 2nd Place, Florida Society of Ophthalmology Resident Research Symposium
2007 – Arnold P. Gold Foundation Humanism and Excellence in Teaching Award, Carilion Roanoke Memorial Hospital
2002 – Alpha Omega Alpha Research Award
2001 – Harvard Hoopes Prize for Excellent Senior Honors Thesis
2000 – Harvard College Scholarship (merit-based)
2000 – Harvard College Research Program Grant (Neuroscience)
1998 – Phi Eta Sigma Honor Society, Duke University
1998 – Dean’s List with Distinction, Duke University
1998 – Howard Hughes Undergraduate Research Grant
1997 – Valedictorian, Bloomingdale High School, Brandon, FL

M. Brandon Parrott, M.D., Ph.D.

Honors and Awards

2016                Top Doctor – Castle Connolly
2011                 Top Ophthalmologist – International Association of Healthcare Professionals
2010-15           Compassionate Doctor Award – Patients’ Choice Organization
2005               In-service Exam Award – Christus St. Joseph Hospital
2004               Most Outstanding Performance in the Clinical Sciences – BCM MD/PhD program
2004               Alpha Omega Alpha Honor Society – BCM
2002               Best Oral Abstract Presentation – Center for Cell and Gene Therapy Symposium – BCM
2001                First Place Poster Presentation – Center for Cell and Gene Therapy Symposium – BCM
2001                First Place Outstanding Platform Presentation – Baylor College of Medicine MD/PhD Symposium – BCM
2001                First Place Speaker Award – Department of Immunology Student Symposium – BCM
1997                 Honors for Academic Performance in the Basic Sciences – BCM
1995-2004     Presidential Scholarship Award – BCM
1995-2004     NIH-Medical Scientist Training Program Fellowship – BCM
1995                Chancellor’s Citation for Extraordinary Academic Achievement – UTK
1995                L. Raymond Shobe Award for Leadership and Academic Excellence in Engineering – UTK
1996                Engineering Science and Mechanics Outstanding Student Scholarship – UTK
1994                Most active member award – Alpha Epsilon Delta (Pre-medical Honor Society) – UTK
1994                Inducted into Tau Beta Pi (Engineering Honor Society)
1990-95         Whittle Scholarship for Leadership and Academic Achievement – UTK
1990               Tennessee Academic Scholar
1990               National Merit Finalist
1990               First Place in the State of Tennessee in TMTA Advanced Calculus Competition

Chapters

Christine Nichols Kay, M.D.

BOOK CHAPTERS

Co-author on chapter on Image Analysis with Dr. Michael Abramoff: Retina, 5^th ed., Editor Stephan Ryan.

Presentations

Christine Nichols Kay, M.D.

PRESENTATIONS AT NATIONAL MEETINGS

[Oral Presentations]

Kay CN et al. ALK-001 (C20-D3-Vitamin A) Slows the Growth of Atrophic Lesions in ABCA4-Related Stargardt Disease: Results of a Randomized, Placebo-Controlled Clinical Trial, the TEASE Study. AAO Subspecialty Day 2023

Kay CN et al. MCO-010 optogenetic vision restoration in retinitis pigmentosa patients with profound vision loss: A randomized, sham-controlled, multi-center, double-masked clinical trial (RESTORE). Retina Society 2023

Kay CN et al. A Phase 1/2 Clinical Trial Evaluating 4D-150, a Dual-transgene Intravitreal Gene Therapy in

Patients with Wet Age-Related Macular Degeneration: Interim 9 Month Results. ASRS 2023

Kay CN et al. “Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1). Macula Society 2023

Kay CN et al. “Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1). Retina Subspecialty Day, AAO 2022

Kay CN et al. ALK-001 (C20-D3-Vitamin A) Slows the Growth of Atrophic Lesions in ABCA4-Related Stargardt Disease: Results of a Randomized, Placebo-Controlled Clinical Trial, the TEASE Study, AAO 2022

Kay CN et al. Qualitative experience of patients and caregivers regarding visual functions and impacts on vision depending activities of daily living and health related quality of life in RPE65-related RP and LCA. ARVO 2021 (virtual due to COVID).

Kay CN et al. “Patient and caregiver experiences of functional vision impairment and health-related quality of life limitations associated with hereditary retinitis pigmentosa.”  Paper presentation (virtual due to COVID), ARVO 2020

Kay CN. “Suprachoroidal delivery for ocular gene therapy: nonclinical experiments evaluating non-viral DNA nanoparticles.” AAO 2019.

Kay CN. “Complement C5 Inhibition as a Potential Treatment for Autosomal Recessive Stargardt Disease (STGD1): Design of a Clinical Trial Assessing a Novel Treatment and Primary Outcome Measure” (Ophthotech trial). Macula Society, Feb 2019.

Kay CN. “Phase 2 Tolerability and Effects of ALK-001 in Stargardt Disease (“TEASE” Trial): An Update.” Macula Society, Feb 2018.

Kay CN. “Phase 2 Tolerability and Effects of ALK-001 in Stargardt Disease (“TEASE” Trial): An Update.” Retina Society, Boston 2017.

Kay CN. “Phase 2 Tolerability and Effects of ALK-001 in Stargardt Disease (“TEASE” Trial): An Update.” ASRS Boston 2017.

Kay CN, Hu J. Angiographic reperfusion of choroidal occlusion and associated recovery in visual acuity and field after rapid anticoagulation. IVFA conference at ASRS, San Diego CA 2014.

Kay CN and Bhalla S. Long-term efficacy and safety of treatment of retinitis pigmentosa with

valproic acid. ASRS 2013.

Kay CN and Bhalla S. Long-term efficacy and safety of treatment of retinitis pigmentosa with

valproic acid. ARVO 2013.

Kay CN, Hollsten J, McClintock, Peden M, Samy H. “A case of fulminant bilateral chorioretinitis

and papillitis.” American Society of Retina Specialists: Las Vegas, Nevada; 2012.

Kay CN, Joshi D, Gray M. Uveal effusion syndrome with associated anterior ischemic optic

neuropathy with dramatic improvement after scleral windows procedure.” American Society of

Retina Specialists: Las Vegas, Nevada; 2012.

Russell SR, Mahajan VB, Boldt HC, Folk JC, Sohn EH, Kay CN, Tarantola RM. “Constellation 2.0:

Eliminating Infusion Bubbles and Uncontrolled Reflux.” Retina Society Meeting: Rome, Italy; 2011

Kay CN, Mullins RF, Kinnick T, Stone EM.  “Morphology of the Vitelliform Lesion in Best Disease.” American Society of Retina Specialists: Vancouver, Canada; August 2010.

Kay CN, Tarantola RM, Folk JC.  Fluorescein case conference: “DUSN.” American Society of Retina Specialists: Vancouver, Canada; August 2010.

Folk JC, Stone EM, Kay CN, et al. “Molecular Genetics of AMD and its response to treatment.”  Paper presentation at 28^th annual meeting of American Society of Retina Specialists, Vancouver, Canada; August 2010.

Potcoava M, Kay CN, Kim MK, Richards DW. “Digital Interference Holography in Ophthalmology.” ARVO 2008.

Kay CN and Pavan PR. “Ocular injuries sustained in paintball trauma.” Free Paper Session.  Fourth International Ophthalmologic School organized by Croatian Society for Cataract and Refractive Surgery. Croatia; May 2008.

Kay CN, Potcoava M, Kim MK, Richards DW.  “Digital Holography Imaging of Human Macula.”  Paper Presentation. Florida Society of Ophthalmology Resident Symposium. Palm Beach, FL; June 2008.

Kay CN, Cohen SM, Pavan PR, Small LB. “A family history study of macular holes.” Gass Society Meeting. Paper presentation. Honolulu, Hawaii; October 2008.

Kay CN, Pavan PR, Kelty PJ. “Ocular injuries sustained in paintball trauma.”  Paper presentation. American Society of Retina Specialists: Maui, Hawaii; October 2008.

Kay CN, Pavan PR. “Case of Lupus causing peripheral neovascularization and tractional retinal detachments.”  Grand Rounds presentation, Women in Retina Symposium, American Society of Retina Specialists: Maui, Hawaii; October 2008.

Kay CN, Potcoava M, Kim MK, Richards DW. “Imaging of Human Optic Nerve with Digital Interference Holography.”  Paper Presentation. Asia ARVO: Hyderabad, India: January 2009.

Potcoava MC, Kim MK, Kay CN. “Wavelength scanning digital interference holography for high-resolution ophthalmic imaging.” SPIE 2009 BiOS Biomedical Optics Symposium 2009. Ophthalmic Technologies XIX, section 3-Ophthalmic Imaging Technology II . San Jose, CA. January 2009.

[Courses at National Meetings]

Kay CN (course organizing faculty) with co-faculty: Jacque L Duncan MD, Isabelle Audo , Ninel Z Gregori MD, Byron L Lam MD, Karmen M Trzupek MS, Janet Davis MD, Kimberly E Stepien MD, Mark E Pennesi MD PhD, Michel Michaelides, MD, Elliott H Sohn MD. AAO 2019. “Retinal Frontiers: Updates in Gene Therapy.”

Kay CN (course organizing faculty) with co-faculty: Ninel Gregori, Benjamin Bakall, Janet Davis, Karmen Trzupek, Kimberly Stepien. Instructional course at ASRS 2019. “Retinal Gene Therapy:
Genetic Testing, Viral Vectors, Surgical Delivery, and Clinical Trials.”

Kay CN (course organizing faculty) with co-faculty: Jacque L Duncan MD, Isabelle Audo , Ninel Z Gregori MD, Byron L Lam MD, Karmen M Trzupek MS, David M Gamm MD, Kimberly E Stepien MD, Mark E Pennesi MD PhD, Michel Michaelides, MD, Elliott H Sohn MD. AAO 2018. “Retinal Frontiers: Updates in Gene Therapy and Stem Cell Therapy.”

Kay CN (course organizing faculty) with co-faculty: Ninel Gregori, Benjamin Bakall, Elliott Sohn, Karmen Trzupek, Instructional course at ASRS 2018. “Retinal Gene Therapy: Clinical and Surgical Overview.”

Kay CN (course organizing faculty) with co-faculty: Jacque L Duncan MD, Isabelle Audo , Ninel Z Gregori MD, Byron L Lam MD, Karmen M Trzupek MS, David M Gamm MD, Kimberly E Stepien MD, Mark E Pennesi MD PhD, Michel Michaelides, MD, Elliott H Sohn MD. AAO 2017. “Retinal Frontiers: Updates in Gene Therapy and Stem Cell Therapy.”

Kay CN (course organizing faculty) with co-faculty: Ninel Gregori, Benjamin Bakall, Elliott Sohn, Janet Davis, Instructional course at ASRS 2017. “Retinal Gene Therapy: Clinical and Surgical Overview.”

Huang S, Kay CN, Maguire A, Humayun M, Kashani A, Duker J, Eliott D. “Future Therapies” instructional course, ASRS 2017.

Kay CN (course organizing faculty) with co-faculty: Jacque Duncan, Kimberly Stepien, Benjamin Bakall, Ninel Gregori, Janet Davis, Karmen Trpuzek. Instructional course at ASRS 2016. “A genetic approach to inherited retinal dystrophies: clinical classification of common retinal dystrophies, genotyping, and gene therapy.”

Kay CN (course organizing faculty) with co-faculty: Jacque Duncan J, Byron Lam, Sandeep Grover, Kimberly Stepien, Isabelle Audo, Ninel Gregory, Karmen Trpuzek. Instructional course at AAO 2016. “A genetic approach to inherited retinal dystrophies: clinical classification of common retinal dystrophies, genotyping, and gene therapy.”

Kay CN (course organizing faculty) with co-faculty: Duncan J, Lam B, Pennesi M, Michaelides M, Sohn E, Audo I. Instructional course at AAO 2015. “A genetic approach to inherited retinal dystrophies: clinical classification of common retinal dystrophies, genotyping, and gene therapy.”

Kay CN (course organizing faculty) with co-faculty: Duncan J, Lam B, Pennesi M, Michaelides M, Sohn E, Audo I. Instructional course at AAO 2014. “A genetic approach to inherited retinal dystrophies: clinical classification of common retinal dystrophies, genotyping, and gene therapy.”

Kay CN and Bakall B.  Instructional course: A genetic approach to inherited retinal dystrophies: updates on clinical classification of common retinal dystrophies, genotyping, and gene therapy.  ASRS 2014 San Diego.

Kay CN and Sohn E.  Instructional course: A genetic approach to inherited retinal dystrophies: updates on clinical classification of common retinal dystrophies, genotyping, and gene therapy.  ASRS 2013, Toronto.

INVITED LECTURES:

Moderator: INNOVATE RETINA AAO 2023

Age related macular degeneration updates (Macular Degeneration Association, Ocala Florida 2022)

LCA updates. VISIONS 2020, Foundation Fighting Blindness.

FDA HEARING FOR VORETIGENE APPROVAL: Invited by Spark Therapeutics to speak on behalf of candidacy of voretigene for FDA approval, Oct 2017. Washington, D.C.  Federal Drug Administration.

FDA ICER hearing for voretigene approval, Invited by Spark Therapeutics as speaker for candidacy of Voretigene approval. Kansas City, Jan 2018.

Updates in Achromatopsia and Stargardt Disease”. Foundation Fighting Blindness, Tampa Chapter, 2018

Retinal Genetics: Overview and Updates.”  University of South Florida.  May 2017.

Rare Diseases: Overview and “The Doctor is in” panel, Foundation Fighting Blindness; Baltimore, MD.  VISIONS 2016.

“The Doctor is in” panel, Foundation Fighting Blindness; Baltimore, MD.  VISIONS 2015.

“Overview: Stargardt disease, Cone-rod dystrophy, Best vitelliform macular dystrophy” – Foundation Fighting Blindness Annual Meeting, VISIONS 2015, Baltimore, MD. VISIONS 2015.

“Gene therapy for CNGB3-associated Achromatopsia: Updates on natural history trial and overview of upcoming Phase 1/2 treatment trial” – post ARVO Gene Therapy Symposium, Denver 2015.

“Gene therapy for CNGB3-associated Achromatopsia: Updates on natural history trial and overview of upcoming Phase 1/2 treatment trial” – University of Wisconsin, June 2015.

Foundation Fighting blindness chapter meeting: Gainesville, FL: “Genetic testing for retinal dystrophies.” September 2014.

“The Doctor is in” panel, Foundation Fighting Blindness; Denver, Colorado.  VISIONS 2014.

“Eylea and the anti-VEGF era” – Department of Pharmacology, University of Florida, December 6, 2014.

Clinical Overview of Achromatopsia:  Achromatopsia National Convention; University of Florida, June 2014.

“Achromatopsia: clinical overview, gene therapy overview/proof of concept in mice and large animals, and clinical trial update.  Institut de Vision; Paris, France. October 2013.

“A genetic approach to inherited retinal dystrophies: updates on clinical classification of common retinal dystrophies, genotyping, and gene therapy.” Croatian Ccataract and Refractive Society.  Zagreb, Croatia. October 2013.

“Overview: Rare retinal dystrophies” – Foundation Fighting Blindness Annual Meeting, VISIONS 2013, Baltimore, MD, June 2012.

“Genetics of Inherited Retinal Disease.”  Invited speaker by Dr. Scott Friedman for Retinal Consultants of Florida sponsored dinner meeting; Lakeland, Florida; April 2013.

Moderator for Vitreoretinal surgical fellow case conference at Vit-Buckle Society; April 2013.

“Diabetic retinopathy for the internist” – January 2012, University of Florida; internal medicine grand rounds

“Translational approach to inherited retinal disease.” Florida Society of Ophthalmology, Orlando, FL June 2012

“Overview: Stargardt disease, Cone-rod dystrophy, Best vitelliform macular dystrophy” – Foundation Fighting Blindness Annual Meeting, VISIONS 2012, Minneapolis, Minnesota, June 2012

“Clinical characterization of inherited retinal disease.” Lions Club, Gainesville, FL; August 2012

“Translational approach to inherited retinal disease.” University of Florida, Pre-Meeting to Inherited Retinal disease Symposium: “Gene Therapy 101”; Gainesville, FL October 2012

“The Doctor is in” panel, Foundation Fighting Blindness, Invited by Jacksonville chapter of FFB, Oct. 2012

“Diabetic retinopathy clinical update” – UF Diabetes Center of Excellence “A celebration of research and patient care”, November 16, 2012.

“A genetic approach to inherited retinal disease,” Retina Pearls at University of Florida, a CME event, December 14, 2012

“Diabetic retinopathy” – January 2013, University of Florida; endocrinology grand rounds

Presentations at Local Meetings

Kay CN: Age-related macular degeneration overview – patient seminar (Villages, October 2023)

Kay CN: A genetic approach to inherited retinal dystrophies: clinical classification of common retinal dystrophies, genotyping, and gene therapy.” April 2016. Gainesville Optometric Society Meeting.

Kay CN: A genetic approach to inherited retinal dystrophies: clinical classification of common retinal dystrophies, genotyping, and gene therapy.” March 2015. Ocala Optometric Society Meeting.

Kay CN, Shifera AS.  “Familial exudative vitreoretinopathy.”  Sarasota Retina Conference; Sarasota, FL  March 2013.

Invited panel discussant/participant: “Clinical management of diabetic retinopathy”; panel members Christine Kay, Susan Bressler, Neil Bressler, Rick Spaide. Sarasota Retina Conference; Sarasota, FL March 2013.

Ryals R, Kay C, Boye S, Min SK, Sun J, Dyka F, Ayala A, Hauswirth W, Boye S. “Targeting photoreceptors via intravitreal delivery of novel, capsid-mutated AAV vectors.” Poster. University of Florida College of Medicine Celebration of Research Day; March 11, 2013.

“Achromatopsia.” Poster, Rare Disease Day, University of Florida; Gainesville, Florida.  February 2013

Meetings Organized

Organized Retina Pearls of Practice and served as moderator at this meeting at University of Florida, December 9, 2012. Guest speakers: Steve Russell (University of Iowa), Timothy Murray (Bascom Palmer)

Organized Inherited Retinal disease symposium held at the University of Florida in October 2012. (Guest speakers: Bill Hauswirth, Gerry Fishman, Sam Jacobson, Jane Sowden, Jacque Duncan, Mina Chung.)

M. Brandon Parrott, M.D., Ph.D.

Oral Presentations

Nov 2015 Oral Platform Presentation – Vision Loss Consequent to Intravitreal Stem Cell Injection
Albini TA, Kuriyan AE, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, Parrott MB, Rosenfeld PJ, Flynn HW
2015 Annual Meeting – American Academy of Ophthalmology – Las Vegas, NV

Nov 2008 Poster – Nosocomial Acute-onset postoperative endophthalmitis at a university teaching hospital Wykoff CC, Flynn HW, Miller D, Parrott MB, Murray TG, Smiddy WE, Davis JL
2008 Annual Meeting – American Academy of Ophthalmology

Nov 2007 Poster – Intravitreal bevacizumab use for progressive ROP and Best disease related choroidal neovascular membranes
Parrott MB, Murray, TG, and Berrocal AM
2007 Annual Meeting – American Academy of Ophthalmology

June 2007 Oral Platform Presentation – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes
Parrott MB, Wykoff CC, and Flynn HW
43rd Annual Bascom Palmer Eye Institute Resident’s Day – Miami, FL

May 2007 Poster – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes
Parrott MB, Wykoff CC, Miller D, Newton J, and Flynn HW
ARVO 2007 Annual Meeting – Fort Lauderdale, FL

June 2003 Oral Platform Presentation – Metabolically Biotinylated Viruses for Vector Targeting and Purification Campos SK, Parrott MB, Adams KE, and Barry MA
Sixth Annual Meeting of the American Society of Gene Therapy – Washington, DC

March 2003 Poster – Metabolically biotinylated gene therapy vectors for vector targeting and purification
Campos SK, Parrott MB, Adams KE, Blum JS, Mok H, Muzykantov V, and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

March 2003 Poster – Selection and application of CLL-targeting peptides using peptide-presenting phage libraries
Takahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

Jan. 2003 Poster – Apoptosis, mitotic rate, and age correlations in the regression of periorbital hemangiomas
Parrott MB, Font RL, and Chevez-Barrios P
Eighty-Second Annual Texas Society of Pathologists Meeting – Houston, TX

June 2002 Oral Platform Presentation – Metabolically biotinylated adenoviral vectors for targeted gene therapy
Parrott MB and Barry MA
Fifth Annual Meeting of the American Society of Gene Therapy – Boston, MA

May 2002 Oral Platform Presentation – Use of in vivo biotinylated adenoviral vectors for targeted gene therapy
Parrott MB and Barry MA
Forty-Third Annual National Student Research Forum – Galveston, TX

Dec. 2001 Poster – Selection of leukemia-targeting peptides using peptide presenting phage libraries
Takahashi S, Barry ME, Parrott MB, Brenner MK, and Barry MA
Forty-Third American Society of Hematology Annual Meeting – Orlando, FL

June 2001 Poster – Metabolically biotinylated gene therapy vectors
Parrott MB and Barry MA
Fourth Annual Meeting of the American Society of Gene Therapy – Seattle, WA

March 2001 Oral Platform Presentation – Metabolically biotinylated adenoviral and retroviral vectors
Parrott MB and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

June 2000 Poster – Metabolic biotinylation of recombinant proteins for viral gene therapy vector targeting
Parrott MB and Barry MA
Third Annual Meeting of the American Society of Gene Therapy – Denver, CO

March 1999 Poster – Selecting lung targeting peptides in vivo
Parrott MB and Barry MA
Cold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY

Posters

Christine Nichols Kay, M.D.

Poster Presentations

Decarlo D, Nowakowski R, Kay CN. “RPE65 Associated Leber Congenital Amaurosis – Phenotype and Treatment.” American Academy of Optometry. 2019.

Banhazi J, Williamson N, Bradley H, Exall E, Naujoks C, Spera C, Green J, Fischer MD, Audo I, Kay C, Viriato D. “What do we know about patients’ and caregivers’ experiences when living with the hereditary retinal condition retinitis pigmentosa?” ISPOR 2019.

Patterson E, Langlo C, Lam B, Kay C, Pennesi M, Weleber D, Fishman G, Hauswirth W, Carroll J. “Assessing color vision in congenital Achromatopsia.” ARVO 2016.

Scholl HP, Shah SM, Kay CN, Tsang SH, Steppien KE, Bernstein PS, Lam BL, Gorin MB, Washington I, Saad L. TEASE: a phase 2 clinical trial assessing the tolerability and effects of oral once-a-day ALK-001 on Stargardt disease. ARVO 2016.

Langlo CS, Erker L, Parker M, Patterson E, Lam B, Kay C, Pennesi M, Weleber R, Fishman G, Hauswirth W, Carroll J and and ACHM-001 study group.  Assessing Foveal Cone Structure in Achromatopsia with AOSLO and SDOCT. ARVO 2016.

Sarfare, S, Min SK, Boye SL, Boye SE, Hauswirth WW, Kay CN. Gene therapy for a mouse model of achromatopsia.  ARVO 2015.

Sarfare S, Min SK, Ruan Q, Boye SL, Boye SE, Hauswirth WW , Kay CN. The expression of CNGB3 provides a long-term rescue in the cone-only CNGB3 x NRL double knock-out (DKO) mouse. ISER 2014.

Choi C, Zhang L, Abramoff MD, Sonka M, Shifera A, Kay CN. Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration with OCT segmentation volumetric analysis.

San Diego, CA: ASRS 2014.

Choi C, Zhang L, Abramoff MD, Sonka M, Shifera A, Kay CN.  Efficacy of Aflibercept in Refractory Wet Age-Related Macular Degeneration. ARVO 2014.

Min SK, Ruan Q, Boye SL, Boye SE, Hauswirth WW, Kay CN. The expression of CNGB3 provides a long-term rescue in the cone-only CNGB3 x NRL double knock-out (DKO) mouse. ARVO 2014.

Radhakrishnan K, Parsons-Wingerter P, Chalam KV, Mames R, Kay C, Grant MB. VESGEN Analysis of Fractal-Based Branching in Arterial and Venous Trees for Investigating Diabetic Retinopathy with Spectralis® Angiographic Imaging. ARVO 2014.

Hauswirth W, Min SH, Boye SL, Kasuga DT, Ruan Q, Sun J, Phan MT,  Boye SE, Kay CN. Natural History of the CNGB3/NRL Double Knock-Out Mouse. ARVO 2013.

In vivo quantification of photoreceptor transduction efficiency using novel modified AAV capsids. Ryals R, Kay CN,  Boye SL, Min SH, Ayala S, Hauswirth WW, Boye SE. ARVO 2013.

Kay CN, Boye S, Ryals R, Sun J, Neeley A, Hauswirth B, Boye S. “Enhanced Retinal Transduction Via The Vitreous With AAV8 Capsid Mutants.”ASRS 2012.

Kay CN, Boye S, Ryals R, Sun J, Neeley A, Hauswirth B, Boye S. “Enhanced Retinal Transduction Via The Vitreous With AAV8 Capsid Mutants.”ARVO 2012.

Kay CN, Tarantola RM, Mullins RF. “Histopathologic Correlation of Retinal Layers on Spectral Domain Optical Coherence Tomography in Post-mortem Human Eyes.” ASRS: Boston, MA; 2011.

Kay CN, Stone EM, Abramoff MD. “Increased thickness of photoreceptor outer segments and retinal pigment epithelium in Best vitelliform macular dystrophy.” ARVO 2011.

Kay CN, Elkins KA, Mahajan VB, Gehrs KM.  “Reversal of Visual Field Defects on Goldmann Perimetry after Fluocinolone Acetonide Implantation for Chronic Uveitis.”  American Society of Retina Specialists: Vancouver, Canada; August 2010.

Kay CN, Tarantola RM, Gehrs KM, Russell SR.  “Non-infectious uveitis following intravitreal bevicizumab.”  Poster presentation.  ARVO 2010.  

Kay CN, Cohen SM, Pavan PR, Small L. “Prevalence of familial trends in a population with macular holes.” Poster presentation.  Retina Congress 2009 NY.

Kay CN, Potcoava M, Kim MK, Richards DW, Pavan PR.  “Digital Holography Imaging of Human Macula.”  Poster Presentation. American Society of Retina Specialists: Maui, Hawaii; October 2008.

Kay CN, Zaccaria AL, Burrows A, Pavan PR. “The OCT findings in retinal phototoxicity.” Poster presentation.  American Society of Retina Specialists: Palm Springs, California 2007.

Nichols C, Seeburg D, Vaishnav H, WC Lara, Feistmann J, Kaushal S, Ratnakaram R.  “Does the use of silicone oil in retina surgery induce glaucoma?” Poster Presentation.  ARVO 2005.

Nichols CM, Miller DW, Johnson JM, Young AB. “Decreased Alpha-Synuclein mRNA Expression in Dementia with Lewy Bodies.” Massachusetts Alzheimer’s Disease Research Center Poster Session, January 2002.

Other

Christine Nichols Kay, M.D.

Grants/Research Experience

2025 – Present

• A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (ARTEMIS)
  NCT06856577
  Role: Principal Investigator
  Sponsor: Adverum

• A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIVOTAL CONFIRMATORY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE

• NCT05956626
  Role: Principal Investigator
  Sponsor: Ocugen

• JADE: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-masked, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of BI 1584862
  NCT06769048
  Role: Principal Investigator
  Sponsor: Boehringer Ingelheim

2024 – Present

• ORACLE Study
  Long-Term Follow-up of GT005 in GA secondary to AMD
  NCT05481827 – Not currently enrolling
  Role: Principal Investigator

• ReNEW Trial
  Elamipretide in Dry AMD
  NCT0637373 – Currently enrolling
  Role: Principal Investigator

• Long-Term Extension Study
  For GA in JNJ-81201887 Parent Study
  NCT06635148 – Enrolling by invitation
  Role: Principal Investigator

• 4D-150 Gene Therapy Trial
  Wet AMD
  NCT05197270 – Currently enrolling
  Role: Principal Investigator

• ACDN-01-001 Trial
  ABCA4-related Retinopathy
  NCT06467344 – Currently enrolling
  Role: Principal Investigator

• EYE103 DME Study
  Phase 2/3 vs. Ranibizumab
  NCT06571045 – Currently enrolling
  Role: Principal Investigator

• RGX-314 Long-Term Study
  Subretinal AMD
  NCT03999801
  Role: Principal Investigator

• SAR402663 Trial
  Intravitreal Dose in Wet AMD
  NCT06660667
  Role: Principal Investigator

• EYP-1901 Phase 3 Trial
  Wet AMD vs. Aflibercept
  NCT04747197
  Role: Principal Investigator

2023 – Present

• NAC Attack Trial
  Oral N-Acetylcysteine for Retinitis Pigmentosa
  Sponsor: NEI
  NCT05537220
  Role: Principal Investigator

2022 – Present

• Pro-EYS Study
  EYS-Related Retinal Degeneration
  NCT04127006 – Not currently enrolling
  Role: Principal Investigator

2021 – Present

• USH2A Retinal Degeneration Study
  NCT03146078 – Not currently enrolling
  Role: Principal Investigator

• X-linked Retinitis Pigmentosa Gene Therapy
  AAV5-RPGR, Sponsor: MeiraGTx/Janssen
  NCT04671433
  Role: Principal Investigator / Surgeon

• GT005 EXPLORE Trial
  Phase II Gene Therapy, Geographic Atrophy
  Sponsor: Gyroscope
  NCT04437368
  Role: Principal Investigator / Surgeon

• GT005 HORIZON Trial
  Phase II, Open-label Gene Therapy for GA
  Sponsor: Gyroscope
  NCT04566445
  Role: Principal Investigator / Surgeon

2021 – Present

• ASCENT Study
  Phase 2, Open-label RGX-314 Gene Therapy via Subretinal Delivery for Neovascular AMD
  NCT05407636
  Sponsor: Regenxbio
  Role: Principal Investigator / Surgeon

• ATMOSPHERE Study
  Phase 2, Open-label RGX-314 Gene Therapy via Subretinal Delivery for Neovascular AMD
  NCT04704921
  Sponsor: Regenxbio
  Role: Principal Investigator / Surgeon

2021 – 2024

• KSI-301 vs. Aflibercept in Diabetic Macular Edema (DME)
  NCT04611152
  Sponsor: Kodiak
  Role: Principal Investigator

• KSI-301 vs. Aflibercept in Retinal Vein Occlusion (RVO)
  NCT04592419
  Sponsor: Kodiak
  Role: Principal Investigator

2020 – 2024

• Zimura for Geographic Atrophy Secondary to AMD
  Phase 3, Sham-Controlled Study
  NCT04435366
  Sponsor: Iveric Bio (formerly Ophthotech)
  Role: Principal Investigator

2020 – 2023

• QR-1123 in Autosomal Dominant Retinitis Pigmentosa (RHO P23H Mutation)
  NCT04123626
  Sponsor: ProQR Therapeutics
  Role: Principal Investigator

2019 – 2024

• SAGA Trial
  Alk-001 for Geographic Atrophy
  NCT03845582
  Sponsor: Alkeus
  Role: Principal Investigator

2019 – 2023

• XIRIUS Trial
  Retinal Gene Therapy for X-linked Retinitis Pigmentosa
  NCT03116113
  Sponsor: Nightstar Therapeutics
  Role: Principal Investigator / Surgeon

2018 – 2019

• Zimura in Stargardt Disease (STGD1)
  NCT03364153
  Sponsor: Ophthotech
  Role: Principal Investigator

2017 – Present

• RUSH2A Study
  Rate of Progression in USH2A-related Retinal Degeneration
  NCT03146078
  Sponsor: Jaeb Center for Health Research
  Role: Principal Investigator

2016 – Present

• AAV Gene Therapy for CNGB3 Achromatopsia
  NCT02599922
  Sponsor: AGTC
  Role: Principal Investigator

• AAV Gene Therapy for CNGA3 Achromatopsia
  Sponsor: AGTC
  Role: Principal Investigator

2015 – Present

• ALK-001 for Stargardt Disease
  Phase 2 Tolerability Study
  NCT02402660
  Sponsor: Alkeus
  Role: Principal Investigator

2013 – 2016

• Achromatopsia Clinical and Genetic Characterization
  NCT01846052
  Sponsor: NEI & AGTC
  Role: Principal Investigator

• QLT091001 in RPE65 or LRAT Mutations
  Phase 2, Inherited Retinal Disease
  Sponsor: QLT
  Role: Principal Investigator (Site startup completed; trial suspended before enrollment)

2011 – 2016

• Foundation Fighting Blindness Career Development Award
  Award Total: $375,000
  Role: Principal Investigator
  “Development and optimization of a viral gene delivery system for CNGB3-associated Achromatopsia”
  Co-sponsors: Dr. Edwin Stone & Dr. William Hauswirth
  University of Florida / Vitreoretinal Associates

2013 – 2014

• NIH Study: ACE2/Ang-(1-7) in Diabetes
  Total Award: $914,139
  Role: Co-Principal Investigator of Clinical Trial Component
  PIs: Dr. Grant & Dr. Raizada
  University of Florida

• Gevokizumab in Non-infectious Uveitis (Eyeguard A Study)
  NCT01747538
  Sponsor: XOMA
  Role: Principal Investigator
  University of Florida

2011 – 2014

• Toxicology Studies for LHON AAV Therapy
  Role: Board-certified ophthalmologist performing safety exams in treated animal models
  University of Florida

2009 – 2011

• OCT in Best Disease: Imaging and Pathogenesis
  Faculty Sponsor: Dr. Edwin Stone
  University of Iowa

• VIEW 1: VEGF Trap-Eye in Wet AMD
  Role: Sub-Investigator
  University of Iowa

• CATT: Comparison of AMD Treatments Trials
  Role: Sub-Investigator
  University of Iowa

2007 – 2009

• Digital Interference Holography in Ophthalmology
  Faculty Sponsors: Dr. Myung Kim & Dr. David Richards
  University of South Florida

2004 – 2005

• Silicone Oil and Intraocular Pressure
  Faculty Sponsor: Dr. R. Ratnakaram
  University of Florida

1999 – 2001

• Alpha-Synuclein Expression in Dementia with Lewy Bodies
  Faculty Sponsor: Dr. Anne Young
  Harvard College Honors Thesis
  Massachusetts General Hospital, Boston

1997 – 1998

• Neurotrophic Factors in Ferret Visual Cortex
  Faculty Sponsor: Dr. Donald Lo
  Duke University Bryan Research Center

Teaching Experience

2014-present   Affiliate assistant professor at University of South Florida – teach lectures to ophthalmology residents, emphasis on inherited retinal disease

3/2016-present   Clinical and surgical preceptor to a pre-med student.

11/12 – 6/14      IDP dissertation committee member for graduate student Renee Ryals, PhD candidate at University of Florida.

8/12-8/14        Rotating medical students mentored in August 2012 in both clinic and lab: Peter Tang (MUSC medical student) and Josh Cohen, Univ of Florida

8/11-8/14        Retina fellowship co-director: (Retina fellows taught: Deval Joshi, M.D.) (2012-2013; Shaminder Bhullar 2012-2012, Brent Rocke 2013-2014)

8/11-10/11        Mentor to Sheena Bhullar for Medical Student Research Program for research for medical students.

8/11- 8/14       MEL4012: serve as faculty mentor to students (Osmanny Gomez, Aureen Arellano, Hannah Hong, Brian Rossmiller) shadowing me for clinical/surgical experience

MEL7933:        faculty instructor for ophthalmology elective at University of Florida

BCC1760:        faculty instructor for surgery clerkship

8/11- 6/14       Faculty Mentor to Renee Ryals for Clinical and Translational Science Institute Program (2012-2014)

8/11-8/14        Assistant professor at University of Florida – teach residents and fellows in clinic and operating room, give lectures on retina and fluorescein angiography

7/09-6/10        Weekly fluorescein conferences – present to residents/faculty

7/09-6/11        Retinal Anatomy – Medical Student Lecture Series

7/09-6/11        Clinical instruction of residents (clinic, surgery, on-call)

Professional Leadership Activities

2010-present   Member of WINR, Women in Retina, ASRS

2012-2014        Steering committee member and Regional direct of RAFA (Retinal advocacy and federal affairs, committee of American Society of Retinal Specialists)

2012-2014        Women in Ophthalmology at University of Florida founder

2011-2014        University of Florida Vitreoretinal Fellowship Director

Director Electrophysiology Service

Director Clinical Research, Vitreoretinal Division

2008-2009    Chief Resident, University of South Florida Ophthalmology

2008               American Retina Foundation delegate for AAO Advocacy Ambassador Program Mid-Year Forum; Washington, D.C.

2008-present   Reviewer for Ophthalmic Surgery, Lasers and Imaging

2012-present    Reviewer for Canadian Journal of Ophthalmology

2002-2003       Vice President, University of Florida AMA Chapter

2002-2003       Atkins Economic Society Chair

Professional Societies

2017-present   Macula Society

2017-present   Retina Society

2009-present   American Society of Retina Specialists

2009-present   Iowa Eye Association

2006-present   American Academy of Ophthalmology

2006-present   ARVO

2006-present   Florida Society of Ophthalmology

2001-present   American Medical Association

2001-2005        American Medical Student Association

2001-2005        Florida Medical Association

Clinical Trials Training at Women in Ophthalmology

Experts advise taking advantage of research opportunities and developing relationships with industry partners.

Click here for the article.

By: Christine Kay, MD,  Lisa M. Nijm, MD, JD

M. Brandon Parrott, M.D., Ph.D.

Clinical Research Protocols

HAWK – NCT02307682 – Efficacy and Safety of RTH258 Versus Aflibercept – The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye. – Alcon.

PROXIMA A – NCT02479386 – Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration – This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study is also intended to generate new information on the relationship between genetics and GA progression. – Hoffmann-La Roche.

CEDAR – NCT02462928 – Safety and Efficacy Study of Abicipar Pegol in Patients With
Neovascular Age-related Macular Degeneration – This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration. – Allergan.

ORBIT – NCT02079883 – Ocriplasmin Research to Better Inform Treatment – Multicenter, prospective, observational, Phase 4 study assessing clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes. – Thrombogenics.

SHORE – NCT01277302 – A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion – This was a Phase IV multicenter, randomized, open-label study, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). – Genentech.

FOVEA (FOV2304) – NCT01319487 – Safety and Efficacy Study of Topical Administration
of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy – The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment. – Fovea Pharmaceuticals SA.

Novartis HMT – NCT01542866 – A 16-Week Evaluation of the Novartis Health Management Tool (HMT) in Age-Related Macular Degeneration – This is a prospective pilot study to evaluate the usability and applicability of a self-monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age-Related Macular Degeneration (AMD) to detect a potential change in disease status. – Novartis Pharmaceuticals.

DODO (FVF4155s) – NCT00533520 – Evaluation of Dosing Interval of Higher Doses of
Ranibizumab – Phase 4 study to test the safety, tolerability and effectiveness of a higher doses (1.0 mg and 2.0 mg) of ranibizumab versus the standard dose (0.5 mg), in adults with age-related macular degeneration who have never been treated with ranibizumab. – Genentech.

VISTA – NCT01363440 – Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema – The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection on the best corrected visual acuity (BCVA) in patients with diabetic macular edema (DME) with central involvement.- Regeneron Pharmaceuticals.

Foresee Home Device Study (PT US 001) – NCT01334294 – Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age-Related Macular Degeneration. – The purpose of the current study is to evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (OCT). – Notal Vision Ltd.

MAHALO – NCT01229215 – A Study of Safety, Tolerability, and Evidence of Activity of
FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy – Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy. – Genentech.